Mesinib
THERAPEUTIC AREA: Oncology / Hematology + Onco-Hematology + Oncology
ACTIVE PRINCIPLE: Imatinib
PRESENTATION: 400 mg x 30 coated tablets and 100 mg x 180 coated tablets
INDICATION:
- GIST
- Chronic Myeloid Leukemia
COUNTRIES WHERE IT IS MARKETED:
